Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Cellectis SA ( (CLLS) ) has shared an update.
On March 19, 2026, Cellectis reported full-year 2025 financial results and a business update, highlighting progress on its allogeneic CAR-T portfolio and gene-editing technologies. As of December 31, 2025, the company held $211 million in cash, cash equivalents and fixed-term deposits, providing funding visibility into the second half of 2027.
The company detailed Phase 1 data for lasme-cel in relapsed or refractory B-ALL, showing an 83% overall response rate at the recommended Phase 2 dose and a 100% response rate in the target Phase 2 cohort, with all such patients becoming eligible for transplant. A pivotal Phase 2 BALLI-01 trial is ongoing, with first interim analysis planned for the fourth quarter of 2026 and a U.S. regulatory filing targeted in 2028.
For eti-cel in relapsed or refractory non-Hodgkin lymphoma, preliminary Phase 1 data presented in December 2025 indicated an 88% overall response rate and 63% complete response rate at the current dose after at least two prior lines of therapy, including prior CD19 CAR-T in most patients. Cellectis is now enrolling a low-dose IL-2 cohort to potentially further improve response durability, with full Phase 1 data expected in 2026.
Beyond clinical programs, Cellectis underscored its technology platform with 2025 data on circular single-stranded DNA as a non-viral donor template showing superior gene-insertion efficiency and persistence versus existing approaches, and safety work on TALE base editors indicating no detectable off-target bias in key genomic regions. These advances are intended to support next-generation non-viral cell and gene therapies and de-risk future engineered cell products.
Partnerships remained an important growth pillar, with activities progressing under a research collaboration with AstraZeneca to develop up to 10 cell and gene therapies and with Servier and Allogene on anti-CD19 and anti-CD70 CAR-T programs, including a pivotal randomized Phase 2 ALPHA3 trial in first-line consolidation LBCL and a completed Phase 1b cohort in renal cell carcinoma. An arbitration ruling in December 2025 partially terminated Servier’s license to one UCART19 product version while preserving Cellectis’ ability to negotiate a direct license, clarifying rights around a key partnered asset.
On the corporate side, Cellectis’ June 26, 2025 shareholders’ meeting approved most board-backed resolutions and refreshed its board by appointing André Muller while two directors departed at the close of the meeting. Management emphasized that 2026 will be a pivotal year as it approaches major clinical readouts that could reshape its competitive position in off-the-shelf CAR-T therapies and influence future partnering and financing options.
The most recent analyst rating on (CLLS) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Cellectis SA stock, see the CLLS Stock Forecast page.
Spark’s Take on CLLS Stock
According to Spark, TipRanks’ AI Analyst, CLLS is a Neutral.
Cellectis SA’s overall stock score is primarily influenced by its strong technical indicators, which suggest positive market momentum. However, the company’s financial performance and valuation are concerning due to persistent unprofitability and negative cash flow, which significantly impact the score.
To see Spark’s full report on CLLS stock, click here.
More about Cellectis SA
Cellectis S.A. is a clinical-stage biotechnology company listed on Euronext Growth and Nasdaq that uses a proprietary gene-editing platform to develop off-the-shelf allogeneic CAR-T cell and other cell and gene therapies. Its pipeline targets high unmet medical needs in oncology, including relapsed or refractory B-cell acute lymphoblastic leukemia and non-Hodgkin lymphoma, and it also advances non-viral gene-editing technologies and partnered programs with large pharma.
Average Trading Volume: 49,911
Technical Sentiment Signal: Hold
Current Market Cap: $248.4M
For an in-depth examination of CLLS stock, go to TipRanks’ Overview page.